New
OXcan
The AI engine Fit Assessment
BetaThe company will be attending the 2024 Health Tech Forward Event
Blurb
OxCan is a startup that uses machine learning and liquid biopsy for early lung cancer detection.
HQ Location
United Kingdom
Founded
2018
Employees
11 - 50
Total funding raised
$5.40M
Last Funding Event
Seed, $3.65M, January 10, 2023
Smart insights
- Catherine Msc (Chief People Officer) worked at Lilium as Head of People Business Partnering for 1.5 years (2021 - 2022)
- Val Miftakhov (Founder & CEO) worked at Google in various roles, including Head of R&D, Google for Work Incubation, for a total of 4 years (2012 - 2016)
- 6m headcount growth: 25%
- 1Y headcount growth: 94%
- Headcount-to-last-round ratio: 5.3 employees/$M
Developer of an artificial intelligence-based healthcare platform designed to identify cancers through targeted blood testing. The company's platform detects cancer materials shed into the blood cost-effectively and routinely and analyses multidimensional liquid biopsy results such as deoxyribonucleic acid, protein and epigenetics, epidemiology, and patient medical history, enabling healthcare providers to get early detection of cancer and curative treatment.